City Therapeutics raised $99.5 million to advance CITY-FXI, a next-generation RNAi therapy in Phase 1 clinical development for the prevention of thromboembolic diseases including stroke and deep vein thrombosis, as well as CITY-RBP4, an RNAi candidate for Stargardt disease, a rare inherited form of juvenile macular degeneration.
